Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.
Saved in:
| Title: | Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis. |
|---|---|
| Authors: | Ferrante, Marc1,2, Peyrin-Biroulet, Laurent3,4,5, Arkkila, Perttu6,7, Armuzzi, Alessandro8,9, Colombel, Jean-Frédéric10, Danese, Silvio11, Faggiani, Roberto12, Guardiola, Jordi13, Hanauer, Stephen B.14, Jahnsen, Jorgen15, Reinisch, Walter16, Roblin, Xavier17, Smith, Philip J.18, Taek Sang Kwon19, Seungmin Kim19, Kyoungwan Nam19, Atreya, Raja20 raja.atreya@uk-erlangen.de |
| Source: | Therapeutic Advances in Gastroenterology. 10/8/2025, Vol. 18, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
